Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2215085
Jan 24, 2024 - Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
0
Why Sanofi (SNY) Might Surprise This Earnings Season
https://www.zacks.com/stock/news/2218829/why-sanofi-sny-might-surprise-this-earnings-season?cid=CS-ZC-FT-tale_of_the_tape|earnings_surprise-2218829
Jan 31, 2024 - Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
0
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619
Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
0
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
https://www.zacks.com/stock/news/2219707/teva-q4-earnings-and-revenues-surpass-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2219707
Feb 01, 2024 - TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
0
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
https://www.zacks.com/stock/news/2239307/aslan-asln-up-161-on-upbeat-initial-data-from-eczema-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239307
Mar 12, 2024 - ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
0
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
https://www.zacks.com/stock/news/2253429/nurix-nrix-up-on-upbeat-initial-data-from-phase-i-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253429
Apr 10, 2024 - Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
0